Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Tracking Targeted siRNA Nanoparticles With In Vivo Imaging

Abstract:
Using nanoparticles tagged with both a fluorescent label and a radioactive isotope of the element copper, a team of investigators at the California Institute of Technology (Caltech) has shown that targeting siRNA-containing nanoparticles to tumors increases tumor uptake rather than tumor localization. The methods that these investigators developed should be broadly applicable to studying nanoparticle biodistribution as part of the preclinical development process.

Tracking Targeted siRNA Nanoparticles With In Vivo Imaging

Bethesda , MD | Posted on November 7th, 2007

Reporting its work in the Proceedings of the National Academy of Sciences of the United States of America, a team led by Mark E. Davis, Ph.D., an investigator in the Nanosystems Biology Cancer Center at Caltech, described the multimodal imaging methods it used to measure biodistribution parameters for siRNA-loaded cyclodextrin-based nanoparticles. Davis' collaborators at Calando Pharmaceuticals, Inc., are preparing to begin a Phase I clinical trial with this siRNA-loaded nanoparticle. Small interfering RNA (siRNA) triggers a naturally occurring mechanism within cells that can silence and regulate targeted genes.

In this study, the investigators used positron emission tomography (PET) to quantify biodistribution of the nanoparticles and imaging to measure siRNA function in a mouse model of human cancer. Some of the nanoparticles were targeted with transferrin, an iron-ferrying protein that binds to a receptor overexpressed by many types of tumors. Although PET data showed that both targeted and untargeted nanoparticles accumulated to a similar extent in tumors, targeted particles reduced the bioluminescent imaging signal by 50 percent compared with nontargeted particles. These nanoparticles were designed so that bioluminescent signal reduction would occur only if the siRNA agent was successfully delivered into cells and reduced expression of its targeted gene. These results show, therefore, that the advantages of targeted nanoparticles appear to be associated with uptake into tumor cells and not with overall tumor localization.

"This work reveals that the primary advantage of targeted nanoparticles for tumor-specific delivery of siRNA is the enhanced uptake in tumor cells rather than altered biodistribution," said Davis. "The conclusions should be applicable to nanoparticle delivery systems in general, and they emphasize why targeted particles should show greater efficacy than nontargeted particles."

This work, which was funded by the NCI's Alliance for Nanotechnology in Cancer, is detailed in the paper "Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging." Investigators from the University of California, Los Angeles, and the University of Freiburg in Germany also participated in this study. This paper is available online at no cost through PubMed Central.

####

About National Cancer Institute
To help meet the goal of reducing the burden of cancer, the National Cancer Institute (NCI), part of the National Institutes of Health, is engaged in efforts to harness the power of nanotechnology to radically change the way we diagnose, treat and prevent cancer.

The NCI Alliance for Nanotechnology in Cancer is a comprehensive, systematized initiative encompassing the public and private sectors, designed to accelerate the application of the best capabilities of nanotechnology to cancer.

Currently, scientists are limited in their ability to turn promising molecular discoveries into benefits for cancer patients. Nanotechnology can provide the technical power and tools that will enable those developing new diagnostics, therapeutics, and preventives to keep pace with today’s explosion in knowledge.

For more information, please click here

Contacts:
National Cancer Institute
Office of Technology & Industrial Relations
ATTN: NCI Alliance for Nanotechnology in Cancer
Building 31, Room 10A49
31 Center Drive , MSC 2580
Bethesda , MD 20892-2580
E-mail:

Copyright © National Cancer Institute

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Nanomedicine

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Fast, efficient sperm tails inspire nanobiotechnology December 5th, 2016

Journal Nanotechnology Progress International (JONPI) Volume 6, issue 2 coming out soon! December 5th, 2016

UTSA study describes new minimally invasive device to treat cancer and other illnesses: Medicine diffusion capsule could locally treat multiple ailments and diseases over several weeks December 3rd, 2016

Discoveries

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Exotic insulator may hold clue to key mystery of modern physics: Johns Hopkins-led research shows material living between classical and quantum worlds December 8th, 2016

ANU invention to inspire new night-vision specs December 7th, 2016

Tokyo Institute of Technology research: 3D solutions to energy savings in silicon power transistors December 6th, 2016

Announcements

Scientists track chemical and structural evolution of catalytic nanoparticles in 3-D: Up-close, real-time, chemical-sensitive 3-D imaging offers clues for reducing cost/improving performance of catalysts for fuel-cell-powered vehicles and other applications December 8th, 2016

Exotic insulator may hold clue to key mystery of modern physics: Johns Hopkins-led research shows material living between classical and quantum worlds December 8th, 2016

Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016

Journal Nanotechnology Progress International (JONPI), newest edition out December 7th, 2016

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project